Alnylam

glossary | media kit | careers | contact us

Capella

Search
Welcome to Capella

Capella is the brightest star in the constellation Auriga. It is also a unified, focused vocal arrangement. For Alnylam, Capella is our online voice for communicating the scientific progress we are making as we translate the science of RNAi into human clinical experience and ultimately towards the development of innovative medicines for patients.

Send us your feedback
Subscribe
See Alnylam At

09/08/2011-09/10/2011
7th Annual Meeting of Oligonucleotide Therapeutics Society

11/20/2011-11/22/2011
International Symposium on FAP
Tags
Regulus, Leadership in RNAi, Delivery, Clinical Trials, RNA-platform, TTR-Mediated Amyloidosis, Severe Hypercholesterolemia, Podcasts, 5x15, RNAi Clinical Trials, Respiratory Syncytial Virus, Liver Cancers, Hemophilia, Huntington’s Disease, RNAi Therapeutics, Refractory Anemia, hemoglobinopathy, Biotherapeutics, VaxiRNA, Huntington's Disease
Archives
Twitter

loading tweets...

More Tweets

December 16, 2011

Podcast: ALN-TTR Phase I Preliminary Results

We recently presented preliminary clinical results for our Phase I study of ALN-TTR01 at the International Symposium on Familial Amyloidotic Polyneuropathy. In this new podcast, Dinah Sah, Ph.D., VP of Research and lead for the ALN-TTR program, discusses the ALN-TTR01 Phase I results she presented at the Symposium, late November. (Length 00:19:32)

This part of our website contains archived information which should not be considered current and may no longer be accurate.

Search

Welcome to Capella

Subscribe

See Alnylam At

Tags

Archives

Twitter

Podcast: ALN-TTR Phase I Preliminary Results